Lung Cancer Trials Ask AI to find trials
WithdrawnNot applicableNCT02298816
Official study title

B-Cell Hematologic Malignancy Vaccination Registry

Study summary

The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and outcomes such as infection in these patients at Aurora Health Care. Additionally hospitalization rates, cost analysis, infection (influenza, pneumonia, other) related to vaccination in this patient population will be evaluated.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forMonoclonal Gammopathy of Undetermined Significance · Multiple Myeloma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 3, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Wake Forest University Health Sciences

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult patients at Aurora Health Care who are newly diagnosed with:
  • Monoclonal gammopathy of undetermined significance (MGUS),
  • Smoldering multiple myeloma (SMM),
  • Multiple myeloma (MM),
  • Waldenstroms Macroglobulinemia (WM),
  • Monoclonal B-cell lymphocytosis (MBL),
  • Chronic lymphocytic leukemia (CLL), or
  • B-Cell Non-Hodgkin lymphoma (NHL).
Reasons someone may not be able to joinExclusion criteria

none

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Aurora Health CareMilwaukee, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 3, 2024. Always confirm current availability with the study team.

View original record ↗